66th ASH Annual Meeting: 802. Chemical Biology and Experimental Therapeutics: Poster III

Symposia: Chemical Biology and Experimental Therapeutics Oral and Poster Abstracts
Poster

Research, Artificial intelligence (AI), Acute Myeloid Malignancies, Combination therapy, AML, Fundamental Science, Apoptosis, Bone Marrow Failure Syndromes, Inherited Marrow Failure Syndromes, Drug development, Translational Research, Genetic Disorders, Genomics, Bioinformatics, Hematopoiesis, Diseases, Immune mechanism, Gene Therapy, Treatment Considerations, Biological therapies, Immunotherapy, Non-Biological therapies, Metabolism, Computational biology, Biological Processes, Myeloid Malignancies, Emerging technologies, Technology and Procedures, Machine learning, Omics technologies

Halls G-H (San Diego Convention Center)

4963

The Nanoparticle-Mediated Delivery of Therapeutic Sirnas Targeting the KMT2A::Afdn Fusion Gene in AML

Manisha Du Plessis¹^*, Luis Daniel Mata Casimiro²^*, Irmela Jeremias, MD^3,4 and Olaf Heidenreich, PhD^2,5,6

¹Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands
²Princes Máxima Center for Pediatric Oncology, Utrecht, Netherlands
³Research Unit Apoptosis in Hematopoietic Stem Cells, Helmholtz Munich, German Research Center for Environmental Health (HMGU), Munich, Germany
⁴German Cancer Consortium (DKTK), partner site Munich, a partnership between DKFZ and the Hospital of the Ludwig-Maximilians-University (LMU), Munich, Germany
⁵Wolfson Childhood Cancer Research Centre, Newcastle University, Newcastle upon Tyne, United Kingdom
⁶University Medical Center Utrecht, Utrecht, Netherlands

4964

Development of Humanized Antibodies Against Vasoactive Intestinal Polypeptide for Increased T Cell Anti-Leukemia Activity

Justin Adeyeye¹^*, Cynthia R. Giver, PhD², Jamie Cohen³^*, Yuou Wang, PhD³^*, Tysheena P. Charles, PhD⁴^*, Khue G. Nguyen, PhD⁵^*, Jian-Ming Li, PhD³^*, Jens Wrammert, PhD⁴^*, David A. Zaharoff, PhD⁵^* and Edmund K. Waller, MD, PhD⁶

¹Winship Cancer Institute Summer Scholars Research Program, Emory University, Atlanta, GA
²Emory University Winship Cancer Institute, Atlanta, GA
³Winship Cancer Institute, Emory University, Atlanta, GA
⁴Department of Pediatrics, Emory University, Atlanta, GA
⁵Department of Biomedical Engineering, North Carolina State University, Raleigh, NC
⁶Emory University, Winship Cancer Institute, Atlanta, GA

4965

Preclinical Efficacy of Decoy-Resistant IL-18 in Hematological Malignancies

Jeffrey N Lindquist, PhD¹^*, Kai Qin, PhD²^*, Jeffrey M Liu, PhD³^*, Aaron M Ring, MD, PhD²^* and Hirdesh Uppal, PhD¹^*

¹Simcha Therapeutics, San Francisco, CA
²Fred Hutchinson Cancer Center, Seattle, WA
³Simcha Therapeutics, New Haven, CA

4966

Abbv-453: A Highly Potent and Selective Next Generation Small Molecule Inhibitor of BCL-2

Darren C Phillips, PhD, BSc^*, Luzivette Robles-Cardona^*, Cory Alvey^*, Justin Ingram^*, Lloyd T Lam, PhD^*, Ziping Yang^*, Jacob J Riehm, MS^*, Jun Chen, MD, PhD^*, Matthew Kurnick^*, Peter Kovar^*, Jin Wang^*, George Doherty^*, Vikram Bhat^*, Yujia Dai^*, Andrew Judd^* and Andrew Souers, PhD

AbbVie Inc., North Chicago, IL

4967

Modulating G-CSFR Signaling Using De Novo Designed Cytokines

Timo Ullrich¹^*, Birte Hernandez Alvarez²^*, Christoph Pollmann³^*, Malte Ulrich Ritter⁴^*, Jérémy Haaf⁵^*, Narges Aghaallaei, PhD⁶^*, Jacob Piehler⁷^*, Ivan Tesakov, MD⁸^*, Maya El-Riz⁹^*, Kateryna Maksymenko¹^*, Valeriia Hatskovska⁵^*, Sergey Kandabarau¹⁰^*, Maksim Klimiankou, PhD¹¹^*, Claudia Lengerke, MD¹², Karl Welte, MD, PhD¹³, Andrei Lupas, PhD¹^*, Julia Skokowa, MD, PhD¹¹ and Mohammad ElGamacy, PhD¹⁴^*

¹Department Protein Evolution, Max Planck Institute for Biology, Tuebingen, DEU
²Department Protein Evolution, Max Planck Institute for Biology, Tuebingen, Germany
³Department of Biology/Chemistry and Center for Cellular Nanoanalytics, Osnabrück University, Osnabrück, Germany
⁴Department of Oncology, Hematology, Clinical Immunology, and Rheumatology, University Hospital Tuebingen, Tuebingen, BW, Germany
⁵Department of Oncology, Hematology, Clinical Immunology and Rheumatology, University Hospital Tuebingen, Tuebingen, DEU
⁶University Hospital Tübingen, Tübingen, DEU
⁷Department of Biology/Chemistry and Center for Cellular Nanoanalytics, University of Osnabruck, Osnabruck, DEU
⁸Department of Oncology, Hematology, Immunology, Rheumatology and Clinical Immunology, University Hospital Tübingen, Tübingen, DEU
⁹Department of Biology/Chemistry and Center for Cellular Nanoanalytics, Osnabrück University, OsnabrüCk, DEU
¹⁰Department of Oncology, Hematology, Clinical Immunology, and Rheumatology, University Hospital Tuebingen, Tuebingen, Germany
¹¹Department of Oncology, Hematology, Immunology, Rheumatology and Clinical Immunology, University Hospital Tübingen, Tübingen, Germany
¹²Department for Internal Medicine II, Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital Tuebingen, Tuebingen, Germany
¹³Pediatric Hematology and Oncology, The University Children's Hospital Tuebingen, Tuebingen, Germany
¹⁴Department of Oncology, Hematology, Clinical Immunology, and Rheumatology, University Hospital Tuebingen, Tuebingen, DEU

4968

Novel MET Inhibitors Provide a Therapeutic Opportunity for AML By Overcoming the Protective Action of the Bone Marrow Niche

Maura Lima Pereira Bueno¹^*, Charles Ayemoba²^*, Anna M Di Staulo²^*, Sen Zhang, PhD²^*, Fernanda Soares Niemann, MSc¹^*, Nádia Ghinelli Amôr, PhD¹^*, Irene Santos, MSc¹^*, Adriana da Silva Santos Duarte, PhD¹^*, Audrey Bastos¹^*, Sara Teresinha Olalla Saad, MD PhD¹, Sandra Pinho, PhD² and Fernanda Marconi Roversi, PhD^1,3^*

¹Hematology and Transfusion Medicine Center, State University of Campinas – UNICAMP, Campinas, Brazil
²Department of Pharmacology & Regenerative Medicine, University of Illinois at Chicago, Chicago, IL
³Department of Surgery, Emory University, Atlanta

4969

Discovery of UBE2B and RNF144b As Potential Candidates for Selective Degradation of NPM1c in AML

Neeraj K Aryal, PhD¹^*, Thomas Frost, PhD¹^*, Yuhan Huang¹^*, Bo Kyung Alex Seong, PhD¹^*, Lisa Drew, PhD¹^* and Omid Tavana²^*

¹AstraZeneca, Waltham, MA
²AstraZeneca Early Oncology R&D TDE, Waltham, MA

4970

Multi-Omic Transcription Regulatory Network Mapping Identifies Targetable Oncogenic TF-Cofactor Relationship between IRF4 and p300 in Multiple Myeloma, and Is Used to Improve TF Protein-Protein Interaction Methodology

Yupeng Zheng, Ph.D.¹^*, Walter F Lenoir, Ph.D.¹^*, Marek J Kobylarz, Ph.D.²^*, Jun Li¹^*, Tamara D Hopkins, PhD²^*, Michael R McKeown, PhD²^*, Michelle G. Shum²^*, Kameron R Mori²^*, Elizabeth C Townsend, Ph.D.¹^*, Benjamin W Trotter, Ph.D.²^*, Peter B Rahl, Ph.D.²^*, Nikolaus D Obholzer, PhD²^* and Charles Y Lin, PhD²

¹Kronos Bio, cambridge, MA
²Kronos Bio, Inc., Cambridge, MA

4971

Targeting Metabolism to Restore Hematopoiesis in Inherited Bone Marrow Failure Syndromes: Preclinical Insights from Zebrafish Models

Sarada Ketharnathan, PhD¹, Serkan Dogan¹^*, Sujata Pokharel¹^*, Sergey V Prykhozhij, PhD¹^*, Anna Cordeiro, PhD²^*, Irina Alecu³^*, William Mannherz, PhD⁴, Mira Liebman, MD⁵^*, Elaine W. Leung, MD, FRCPC⁵, Steffany Bennett³^*, Miroslava Cuperlovic-Culf⁶^*, Suneet Agarwal, MD, PhD⁴, Yigal Dror, MD, FRCPC⁷ and Jason N. Berman, MD¹

¹CHEO Research Institute, Ottawa, ON, Canada
²AGADA Biosciences, Halifax, NS, Canada
³Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, ON, CAN
⁴Boston Children's Hospital, Boston, MA
⁵Children's Hospital of Eastern Ontario, Ottawa, ON, CAN
⁶Digital Technologies Research Centre, National Research Council of Canada, Ottawa, ON, CAN
⁷Marrow Failure and Myelodysplasia Program, Division of Haematology and Oncology, The Hospital for Sick Children, Toronto, ON, Canada

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH